About Chugai

We dedicate ourselves to adding value by creating and delivering innovative products and services for the medical community and human health around the world.

Everything we do is based on this mission.

We work for the wellbeing of each and every patient, who all have different lifestyles, values, treatment needs, and priorities, and for the advancement of medical care around the world.

We believe that pursuing innovation with new ideas leads to sharing value with all stakeholders.

Chugai’s Strengths

Chugai’s Strengths

Strengthened by unique science and technology
R&D-oriented pharmaceutical company

Chugai is working to satisfy unmet medical needs by developing innovative new drugs using its unique technology and science, including antibody engineering technology.

Chugai has gained a reputation worldwide for its high level of drug discovery capabilities, backed by a diverse research infrastructure, including the advancement of unique antibody engineering technologies.

Unique Technology and Science

Creation of the first therapeutic antibody originating in Japan. World-leading technological capabilities in antibodies and mid-size molecules

  • Share of therapeutic antibody sales in Japan*1

    No.1

  • Breakthrough Therapeutics Designations*2 *2

    9times

  • Innovative new drugs
    as a percentage of sales*3

    65%

  • Countries approving Chugai products

    More than
    110

  • *1 Copyright © 2024 IQVIA. Calculated based on JPM 2023.Reprinted with permission. The scope of the market is defined by Chugai.
  • *2 A system introduced in July 2012 by the U.S. Food and Drug Administration aimed at expediting the development and review of drugs for the treatment of severe or life-threatening diseases or symptoms.
  • *3 Proportion of sales from products that qualify for premium pricing.

One of Japan's top prescription pharmaceutical manufacturers

  • Sales Revenue

    1trillion
    1,706
    billion yen

    • (Consolidated, fiscal year ending December 2024)
  • Operating profit

    5,561
    billion yen

    • (Consolidated, fiscal year ending December 2024)
  • Number of Employees

    7,778

    • (Consolidated, as of December 31, 2024)

Business Strategy

Based on the strategic alliance with Roche, we aim to "achieve advanced, sustainable patient-centric healthcare"

Chugai's basic management policy is "Creating Shared Value," and we aim to solve social issues and achieve sustainable development. We will create shared value by "realizing advanced, sustainable patient-centric healthcare" through innovation that only we can produce by making the most of our science and technology and our unique business model based on our strategic alliance with Roche.

History of Chugai Pharmaceutical

History of Chugai Pharmaceutical

A company that continues to innovate while carrying on the spirit of its founding

Our founding spirit in 1925 was to "make drugs that benefit society."

Even after 100 years have passed, our founding commitment to "for patients" remains unchanged.

Contents List